MedTrace Logo

Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia

NCT01121042 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2020-10-14

No results posted yet for this study

Summary

The aim of this study is to evaluate the overall effectiveness of Ondansetron as an adjunctive or "add-on" medication in the treatment of Schizophrenia. This study is a double blind, placebo-controlled, randomised, 12 week trial.

Conditions

Interventions

DRUG

Ondansetron

8mg per day oral capsule

DRUG

Placebo

daily oral capsule matched to active study medication. Made form 100% lactose powder

Sponsors & Collaborators

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • Professor Jayashri Kulkarni · Monash Alfred Psychiatry Research Centre (MAPrc)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01121042 on ClinicalTrials.gov